About Artelo Biosciences, Inc. - Common Stock (ARTL)
Artelo Biosciences Inc is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology and pain management. The company is dedicated to advancing its proprietary drug candidates that target the endocannabinoid system, aiming to improve patients’ quality of life and treatment outcomes. Through its research and development efforts, Artelo seeks to harness the therapeutic potential of cannabinoids and related compounds, striving to bring new solutions to difficult-to-treat conditions. Read More
The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft).
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Synergy CHC Corp. (NASDAQ: SNYR), a rising consumer staple health company, has announced a wave of major expansion throughout North American for its FOCUSfactor® supplements and functional beverage brands, across mass, grocery, convenience, and wholesale channels. Functional Beverage Momentum
The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.
